Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)

NCT05046821 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.

NCT NCT05046821
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05046821 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Influence of NT5c1A Antibodies on Disease Progression, Clinical Phenotype and Blood and Muscle Biomarkers in Sporadic Inclusion Body Myositis - A Prospective Evaluation (INSPIRE-IBM Study)
Lead sponsor
University of California, Irvine
Phase
Observational
Overall status
Active, not recruiting
Start date
October 11, 2021
Completion date
March 31, 2027
Enrollment
150 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

inclusion body myositis, sporadic inclusion body myositis